| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 8592- | FS, | Tras, | Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474) |
| - | in-vitro, | BC, | BT20 |
| 8595- | FS, | Tam, | Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice |
| - | in-vitro, | BC, | MCF7 |
| 8599- | FSO, | Cancer chemopreventive potential of the Egyptian flaxseed oil in a rat colon carcinogenesis bioassay--implications for its mechanism of action |
| - | in-vivo, | CRC, | NA |
| 8601- | FSO, | Differential Response of Two Human Breast Cancer Cell Lines to the Phenolic Extract from Flaxseed Oil |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF-10AT |
| 7010- | Fuc, | Fucoidan enhances the effect of chemotherapeutic drug against drug-resistant lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | vitro+vivo, | APL, | APL NB4 |
| 7019- | Fuc, | Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43 |
| - | vitro+vivo, | HCC, | HUH7 |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 1039- | Fuc, | Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network |
| - | in-vitro, | Var, | NA |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 7041- | GA, | Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway |
| - | vitro+vivo, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | Nor, | HK-2 |
| 7037- | GA, | Chit, | Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7042- | GA, | Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 7044- | GA, | QC, | Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity |
| - | in-vitro, | BC, | MCF7 |
| 7046- | GA, | Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
| - | in-vitro, | NSCLC, | A549 |
| 7031- | GA, | Cisplatin, | Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 1091- | GA, | Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | HTB-35 |
| 1115- | GA, | Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway |
| - | in-vivo, | GC, | GES-1 |
| 7051- | Gallo, | MET, | Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 7053- | Gallo, | Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Bxpc-3 |
| 5207- | Gallo, | Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism |
| - | in-vitro, | PC, | NA |
| 5206- | Gallo, | Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells |
| - | in-vitro, | Var, | NA |
| 935- | Gallo, | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 2060- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 1958- | GamB, | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
| - | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
| 1957- | GamB, | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
| - | in-vitro, | ESCC, | EC9706 |
| 7066- | GamB, | Unravelling the Therapeutic Potential of Gambogic Acid: Deciphering Its Molecular Mechanism of Action and Emerging Role as an Anticancer Xanthone |
| - | Review, | Var, | NA |
| 7060- | GamB, | New targets for the antitumor activity of gambogic acid in hematologic malignancies |
| - | Review, | Melanoma, | RPMI-8226 |
| 7059- | GamB, | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT15 |
| 7087- | GAR, | Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential |
| - | Review, | Var, | NA |
| - | in-vivo, | Nor, | NA |
| 7088- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC4 |
| 7091- | GAR, | Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | Var, | NA |
| 811- | GAR, | Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 810- | GAR, | GEM, | Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures |
| - | in-vitro, | PC, | NA |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF7 |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 797- | GAR, | CUR, | Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | SaOS2 |
| 7213- | GAs, | Anti-Cancer Properties of Ginkgolic Acids in Human Nasopharyngeal Carcinoma CNE-2Z Cells via Inhibition of Heat Shock Protein 90 |
| - | vitro+vivo, | NPC, | CNE2 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | H1975 |
| 7233- | GAs, | Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis |
| - | in-vitro, | Laryn, | HEp2 |
| 7226- | GBE, | Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways |
| - | vitro+vivo, | Lung, | NA |
| 7223- | GBE, | Ginkgo biloba Exocarp Extract Inhibits the Metastasis of B16-F10 Melanoma Involving PI3K/Akt/NF- κ B/MMP-9 Signaling Pathway |
| - | vitro+vivo, | Melanoma, | B16-F10 |
| 1189- | GBE, | New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer |
| - | Review, | Var, | NA |
| 7103- | GEN, | A Comprehensive Review of Genistein's Effects in Preclinical Models of Cervical Cancer |
| - | Review, | Cerv, | NA |
| 7102- | GEN, | Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid